BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 14518303)

  • 21. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Morphology and biology of invasion with Barret's carcinoma as an example].
    Werner M; Walch A
    Verh Dtsch Ges Pathol; 2000; 84():62-8. PubMed ID: 11217450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased expression of the cyclin D1 gene in Barrett's esophagus.
    Arber N; Lightdale C; Rotterdam H; Han KH; Sgambato A; Yap E; Ahsan H; Finegold J; Stevens PD; Green PH; Hibshoosh H; Neugut AI; Holt PR; Weinstein IB
    Cancer Epidemiol Biomarkers Prev; 1996 Jun; 5(6):457-9. PubMed ID: 8781742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis.
    von Rahden BH; Stein HJ; Feith M; Pühringer F; Theisen J; Siewert JR; Sarbia M
    Mol Carcinog; 2006 Oct; 45(10):786-94. PubMed ID: 16921482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53-mutant clones and field effects in Barrett's esophagus.
    Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
    Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta 1 integrin expression in adenocarcinoma of Barrett's esophagus.
    Bottger TC; Youssef V; Dutkowski P; Seifert J; Maschek H; Brenner W; Junginger T
    Hepatogastroenterology; 1999; 46(26):938-43. PubMed ID: 10370643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allelic loss involving the tumor suppressor genes APC and MCC and expression of the APC protein in the development of dysplasia and carcinoma in Barrett esophagus.
    Bektas N; Donner A; Wirtz C; Heep H; Gabbert HE; Sarbia M
    Am J Clin Pathol; 2000 Dec; 114(6):890-5. PubMed ID: 11338478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
    Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
    Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation.
    Wongsurawat VJ; Finley JC; Galipeau PC; Sanchez CA; Maley CC; Li X; Blount PL; Odze RD; Rabinovitch PS; Reid BJ
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):509-16. PubMed ID: 16537709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 is frequently mutated in Barrett's metaplasia of the intestinal type.
    Campomenosi P; Conio M; Bogliolo M; Urbini S; Assereto P; Aprile A; Monti P; Aste H; Lapertosa G; Inga A; Abbondandolo A; Fronza G
    Cancer Epidemiol Biomarkers Prev; 1996 Jul; 5(7):559-65. PubMed ID: 8827361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in gene chip technique in Barrett's metaplasia and adenocarcinoma.
    Wang XW; Gao HJ; Fang DC
    J Dig Dis; 2008 May; 9(2):68-71. PubMed ID: 18419638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular markers and genetics in cancer development.
    Hormi-Carver K; Souza RF
    Surg Oncol Clin N Am; 2009 Jul; 18(3):453-67. PubMed ID: 19500736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic and molecular analysis of high-grade dysplasia and early adenocarcinoma in short- versus long-segment Barrett esophagus.
    Nobukawa B; Abraham SC; Gill J; Heitmiller RF; Wu TT
    Hum Pathol; 2001 Apr; 32(4):447-54. PubMed ID: 11331963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):736-9. PubMed ID: 18349297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of CD44v5 and -v6 in Barrett's carcinoma is not increased compared to that in nondysplastic Barrett's mucosa.
    Menges M; Goebel R; Pueschel W; Zeitz M; Stallmach A
    Exp Mol Pathol; 2002 Jun; 72(3):207-12. PubMed ID: 12009784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
    Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
    Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neosquamous epithelium does not typically arise from Barrett's epithelium.
    Paulson TG; Xu L; Sanchez C; Blount PL; Ayub K; Odze RD; Reid BJ
    Clin Cancer Res; 2006 Mar; 12(6):1701-6. PubMed ID: 16551852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.